



Published in final edited form as:

Microbiol Spectr. 2019 March ; 7(2): . doi:10.1128/microbiolspec.GPP3-0007-2018.

Group B Streptococcus (*Streptococcus agalactiae*)

Vanessa N. Raabe^{1,2} and Andi L. Shane²

¹Divisions of Infectious Diseases, Emory University School of Medicine, 500 Irvin Ct, Rm 243, Decatur, GA 30030. Telephone: (404) 712-9380.

²Division of Pediatric Infectious Disease, Emory University School of Medicine and Children's Healthcare of Atlanta, 2015 Uppergate Drive NE, Rm. 504A, Atlanta, GA, 30322. Telephone: (404) 727-5642. Fax: (404) 727-9223.

Summary

Invasive disease due to group B *Streptococcus* infection (*Streptococcus agalactiae*) results in a wide spectrum of clinical disease. In North America, serotypes Ia, Ib, II, III, and V are most frequently associated with invasive disease. Group B *Streptococcus* remains a continued source of morbidity and mortality in high-risk populations, including pregnant women, neonates, and the elderly; an increasing incidence of invasive disease has been observed in non-pregnant adults. Group B *Streptococcus* remains the most common culture-confirmed neonatal bacterial infection in the United States and is a significant source of neonatal morbidity globally. Intrapartum antibiotic prophylaxis has reduced the incidence of early onset neonatal disease without a notable impact on the incidence of late onset neonatal disease. Penicillin G remains the mainstay of therapy although reduced penicillin susceptibility has been observed in select isolates. Increased frequency of resistance to non-beta-lactam antibiotics, including clindamycin, erythromycin, and fluoroquinolones, has been observed with some isolates demonstrating resistance to vancomycin. The development and implementation of strategies to identify hosts, treat judiciously with antimicrobials with the narrowest spectra, and prevent invasive disease, with vaccines, are essential to reduce the burden of group B *Streptococcus* disease.

Introduction

Streptococcus agalactiae, also known as Group B *Streptococcus* (GBS), was first differentiated from other streptococci by Rebecca Lancefield in the 1930s after it was isolated from milk and cows with bovine mastitis (1). Lancefield described GBS colonization of the vaginal tract of asymptomatic women, however, human pathogenicity was not described until 1938 when three reports of fatal post-partum infection were published (2, 3). Invasive GBS disease was rarely identified in humans until the 1960s, when increasing reports of adult and neonatal invasive infections were published (4–7). The incidence of invasive GBS disease continues to increase and it remains a significant pathogen among both infants and adults.

Streptococcus agalactiae has historically been divided into nine serotypes (Ia, Ib, II, III, IV, V, VI, VII, VIII) based on the capsular polysaccharide (8). A tenth serotype (IX) was described in 2007 (9). Among non-pregnant adults in the United States (US), the most common serotype causing invasive disease is group V (29% in 2005–2006) followed by serotypes Ia, II, and III (10). A study from Alberta, Canada of serotypes associated with invasive GBS disease from 2003–2013, demonstrated that the most frequent serotype was III (20%) followed closely by serotypes V (19%), Ia (19%), Ib (13%), and II (11%) (11). The dominant serotypes causing disease varies regionally and differs by invasive and colonizing isolates.

Clinical Manifestations

The most common syndromes due to invasive GBS disease in adults are bacteremia without a focus and skin/soft tissue infections (10, 12–16). The former often presents with altered mental status, chills, and fevers (8). Bacteremia may also occur secondary to a focal source of infection; polymicrobial bacteremia, most commonly with *Staphylococcus aureus*, may be seen in 26%–45% of cases (17, 18).

Streptococcus agalactiae bacteremia may lead to seeding of the cardiac valves and endocarditis. Vegetations in GBS endocarditis may become extremely large with a high risk of embolization (19, 20). In the 1930s and 1940s, GBS endocarditis predominantly was associated with acute disease in pregnant and post-partum women, primarily involving the mitral valve (20). Rheumatic heart disease was a common predisposing factor and embolization of vegetations from valves to the kidneys and spleen was common (20). The epidemiology of GBS endocarditis has evolved over time; a case series beginning in the 1960s described endocarditis affecting men and non-pregnant women, involvement of the aortic and tricuspid valves, and subacute presentations (20). The percentage of GBS infections manifesting as endocarditis is in decline, from 9% in one study conducted in Atlanta in 1982–1983 to approximately 3% of GBS infections in the US in a study from 1990–2007 (10, 15). Although cardiac valve abnormalities are a risk factor for GBS endocarditis, cases have been described in structurally normal hearts (21–23). Mortality from GBS endocarditis may be quite high despite medical and surgical interventions with 41% mortality in one case series of 27 patients from 1984–2004 (21).

Skin and soft tissue infections attributed to GBS may manifest as cellulitis, abscesses, foot infection, or decubitus ulcers (24, 25). Diabetes mellitus is a common underlying condition in patients with GBS skin and soft tissue infections (13). Necrotizing fasciitis and pyomyositis attributed to GBS has occasionally been described (18, 25, 26).

Acute and chronic osteomyelitis attributed to GBS has been reported in neonates, children, and adults (27). Infection may arise from direct inoculation from overlying skin/soft tissue infection, skin breakdown such as a decubitus ulcer, or via hematogenous seeding (27). Septic arthritis due to GBS is usually monoarticular although multiple joints may be involved (28, 29). Any joint may be infected but commonly affected joints include the knee, ankle, and shoulder (28, 29). Septic arthritis may involve prosthetic joints with the majority of infections occurring at least 3 months after prosthesis placement; some GBS prosthetic

joint infections require prosthesis removal in addition to antimicrobial therapy for successful treatment (30–32).

Group B *Streptococci*, concurrently with other organisms, have been implicated in pneumonia (33). Imaging findings may include unilateral or bilateral lobar infiltrates (33). Dementia, neurological disease, and tracheoesophageal fistulae are associated with GBS pneumonia, likely due to increased risk of aspiration of the organism (34). Colonization of the airway with GBS is infrequent in patients with cystic fibrosis and when it occurs, does not appear to be associated with worse clinical outcomes (35).

Meningitis is a severe manifestation of invasive GBS disease. It is uncommon in adults but a common manifestation of late onset GBS infection in neonates (36). Infants who survive the acute phase of the GBS meningitis infection may have significant cognitive or neurological sequelae; 32–44% of infants who survived GBS meningitis have neurodevelopmental impairment with severe impairment occurring in up to 19% of surviving infants (37, 38).

Another manifestation of GBS disease includes urinary tract infections. Urinary tract infections may be associated with a variety of GBS serotypes (39). In men, GBS may be associated with prostatitis (34, 40). Group B *Streptococcus* bacteriuria in women during pregnancy is a risk factor for late gestational maternal colonization with GBS and early onset neonatal GBS infection (41, 42).

Pregnant Women

Pregnancy has been associated with a high incidence of invasive GBS disease. In a multi-state evaluation from 2007–2009, the incidence of invasive disease due to GBS was twice as high in pregnant women (0.04/1,000 woman-years) compared to non-pregnant women (0.02/1,000 woman-years) (43). Although the majority of GBS infections are detected during labor and delivery, women in the post-partum period are also at an increased risk for invasive GBS disease even in the absence of other predisposing conditions (43, 44). Rates of maternal invasive GBS disease in the US vary by state, with rates ranging from 0.1 per 1,000 deliveries to 0.8 per 1,000 deliveries (45). Worldwide, the incidence of systemic invasive GBS disease in pregnant women is estimated at 0.38 cases per 1,000 pregnancies with a case fatality rate of 0.2% (44). Serotypes Ia and III account for over half of maternal systemic GBS disease, followed by serotypes V, Ib, and II (44). Systemic maternal GBS disease is associated with increased odds of premature delivery and sepsis in infants (44).

Asymptomatic rectovaginal colonization rates among pregnant women vary widely worldwide [Figure 1] although the majority of estimates fall between 5%–30% (46–97). A recent review estimated that 18% of pregnant women worldwide are colonized with GBS, of which 98% of isolates were serotypes I–V, although there was regional variability in serotype distribution (98). In this study, colonization rates were highest among pregnant Caribbean women at 35% and lowest among pregnant East Asian women at 11% (98). Estimates of GBS colonization in the US range from 10–30% (94–96). Colonization of GBS may be intermittent throughout pregnancy although 17%–28% of women with vaginal or rectal colonization in the first trimester have sustained colonization in the second and third

trimesters or at term (99). Women with GBS colonization during pregnancy were recently found to have a 1.21 risk ratio for preterm birth compared to women without GBS colonization, with a higher risk ratio (1.98) observed in women with GBS bacteriuria (100).

Risk factors associated with maternal GBS intrapartum vaginal or rectal colonization include GBS bacteriuria during the current pregnancy and a history of GBS colonization in a previous pregnancy (41, 101, 102). In one study of pregnant women, no significant difference in the composition of the vaginal and rectal flora between GBS colonized and non-colonized women was observed (99). Studies examining the role of the composition of the vaginal microbiota in relation to colonization with GBS in non-pregnant women have similarly demonstrated no differences in the α -diversity or carriage of *Lactobacillus* between women with and without GBS colonization (103). The role of probiotic administration on GBS carriage remains unclear. One study of *Lactobacillus rhamnosus* and *Lactobacillus reuteri* administered to 110 women with detectable GBS colonization at 35–37 weeks gestation until delivery demonstrated 43% of women in the probiotic group subsequently had negative GBS screens at delivery compared to 18% in the placebo group; however, there were no significant differences in fetal outcome (104). However, in another placebo-controlled study of 34 women who received a 21 day course of *Lactobacillus rhamnosus* and *Lactobacillus fermentum/reuteri* probiotics after a positive GBS screen at 36 weeks, no difference in GBS colonization rates after completion of the supplementation and no difference in infant health was observed between the placebo and probiotic recipients (105).

Non-Pregnant Adults

Although traditionally thought of as a disease afflicting infants and pregnant women, the incidence of GBS disease is increasing among non-pregnant adults, from 3.6 cases/100,000 persons in 1990 to 7.3 cases/100,000 persons in 2007, based on surveillance in 10 US states (10). Comorbidities are present in most adults with invasive GBS disease, including heart disease, neurological disorders, kidney disease, liver disease, alcohol abuse, smoking, obesity, malignancy, and immunocompromising conditions (10, 13, 106). Diabetes mellitus is a common comorbidity, particularly among patients with skin/soft tissue infections (10, 13, 106). Higher incidences and mortality rates from GBS disease have been observed among those of black race compared to white race, although the reason for this difference remains unclear (10, 13, 106).

Older Adults

Higher incidence rates of invasive GBS disease among persons ages 65 or older compared to the general non-pregnant adult population have been described in the US [Figure 2], Canada, the United Kingdom, and multiple European countries (13, 107–111). Annually, invasive GBS affects 25/100,000 adults ages 65 and older in the US (94). The elderly population accounted for approximately 40% of invasive cases reported in the US in 2015 with a higher incidence of deaths (1.08–4.73 deaths/100,000 persons) compared to the incidence of death in the general population (0.54 deaths/100,000 persons) (111). An estimated 12% of elderly long-term care facility residents are colonized with GBS while an estimated 22% of community-dwelling elderly adults in Houston in one study were colonized with GBS, with

47% carrying serotype V (24, 112). Invasive GBS disease in the elderly commonly presents as bacteremia, urinary tract infection, skin infection, and pneumonia (110, 113). Risk factors for GBS disease in the elderly population include being bedridden and residence in a long-term care facility (107, 110).

Neonatal Disease

Group B *Streptococcus* is the leading etiology of culture-confirmed neonatal bacterial infection in the US and resulting in significant mortality (114). Invasive neonatal GBS disease may be divided into early onset disease (EOD), occurring <7 days of life, and late onset disease (LOD) occurring between 7–90 days of life. Serotypes I-V account for 97% of invasive neonatal GBS disease with serotype III accounting for nearly half (43%) of EOD and 73% of LOD (36). Estimates of the incidence of EOD GBS disease range from 0.7 cases/1,000 live births in 1997 to 0.21–0.25 cases/1,000 live births in 2014 and 2015 [Figure 3] (111, 114–133). Disease due to *Streptococcus agalactiae* has been found in 0.58% of neonates with encephalopathy who meet criteria for cooling, a more than 10-fold increase compared to all live term infants. These infants have double the risk of fatality compared to those with neonatal encephalopathy without associated GBS disease (134). Worldwide, estimates of EOD cases per 1,000 live births vary from country to country with incidences of 0.09 in Japan, 0.58 in Panama, 0.76 in Hong Kong, 0 to 1.5 in South Africa, and 2.35 in the Dominican Republic, with a pooled estimate of 0.49 cases per 1,000 live births (36, 135–137). Overall, rates of EOD are highest in Africa and lowest in Asia (36). Worldwide, the pooled incidence of LOD is 0.26 cases per 1,000 live births (36). In the US, the estimated incidence of LOD is 0.32 cases per 1,000 live births [Figure 3] (111, 138).

Risk factors for EOD disease include maternal vaginal or rectal GBS colonization, GBS bacteriuria during pregnancy, prolonged labor, prolonged rupture of membranes, low birth weight, prematurity, intrapartum fever, and systemic maternal GBS disease (42, 44, 139). HIV-exposure does not appear to be a risk factor for EOD (140). The risk factors for the development of LOD are not as well understood as for EOD; known risk factors include prematurity and black race (138, 141). While maternal GBS colonization increases the risk of developing LOD, it does not appear to be as strong of a risk factor as for EOD (138, 141). Infants exposed to HIV have a 4.43 higher likelihood for developing LOD compared to unexposed infants (140).

Early onset disease is attributed to vertical transmission of GBS from the mother either due to ascending infection from the genital tract or infection obtained during passage through the vaginal canal at delivery; symptom onset may be subtle and may be noted within 24 hours after birth (36, 142). Typical manifestations of EOD include bacteremia and pneumonia while meningitis, bone and joint, and soft tissue infections are less common (114). Late onset disease is attributed to horizontal acquisition of GBS. Rarely, LOD has been attributed to GBS transmission from human milk among women with GBS mastitis (143). Meningitis is more common in LOD than EOD although LOD may present as bacteremia, urinary tract infection, bone/joint infection, pneumonia, or soft tissue infections (36, 138, 139).

Neonatal invasive GBS disease overall results in case fatality rates ranging from 1%–8.4% in term infants to 5%–20% in preterm infants (36, 139). For EOD, mortality rates vary worldwide; in resource-endowed countries the estimated case fatality risk is 5% but a much higher risk, up to 27%, has been observed in Africa (36). Mortality from EOD in the US is estimated at 7% with higher mortality in low birth weight and premature infants (114). Worldwide, LOD is estimated to have a case fatality rate of 7% (36). In addition to early and late onset invasive disease, *in utero* GBS disease accounts for approximately 1% of stillbirths worldwide and up to 4% of stillbirths in Africa (144).

Prevention of Neonatal Disease

Due to the burden of GBS disease in neonates, preventative measures have been developed to minimize invasive disease. Maternal antibiotic administration to prevent neonatal GBS disease began in 1973 (145). Intrapartum antibiotic prophylaxis reduces EOD among infants born to GBS colonized women by 86%–89% (42). In countries without a national policy on intrapartum antibiotic prophylaxis, approximately 1.1% of infants born to GBS colonized mothers develop EOD due to GBS, whereas in countries with intrapartum antibiotic prophylaxis recommendations, the risk decreases to 0.03% (146). Penicillin or ampicillin administered at least 4 hours prior to delivery is first-line therapy for intrapartum antibiotic prophylaxis while cefazolin may be used for penicillin-allergic patients without anaphylaxis, angioedema, respiratory distress, or urticaria (42). In patients with severe penicillin allergy, testing of the GBS isolate for clindamycin susceptibility is recommended with use of intrapartum clindamycin for susceptible isolates and vancomycin for resistant isolates (42). Both risk-based and culture-based models for determining when to administer intrapartum antibiotic prophylaxis are currently in use worldwide and vary by geographic region (147). The United Kingdom does not recommend routine GBS screening cultures for pregnant women and uses risk-based algorithms to guide intrapartum antibiotic prophylaxis, whereas the US, Canada, Australia, and New Zealand recommend universal screening with GBS cultures (42, 97, 148, 149). Adherence to intrapartum antibiotic prophylaxis guidelines varies widely; estimates of adherence in countries with universal culture-based screening programs range from 20% to 95% while adherence estimates range from 10% to 50% in countries with risk-based screening programs (147).

Guidelines regarding intrapartum antibiotic prophylaxis for GBS in the US were first issued in 1996 and have undergone several updates, most recently in 2010. The current 2010 guidelines recommend a screening culture from the vagina and rectum of all pregnant women between 35–37 weeks gestation to assess for colonization with GBS and offering intrapartum prophylaxis to all women with positive screening cultures, a history of GBS bacteriuria during the current pregnancy, or a previous infant affected by EOD GBS disease (42). Since the institution of intrapartum antibiotic prophylaxis in the US, the incidence of invasive early onset GBS disease has declined from 1.7 cases/1,000 live births in 1993 to 0.76–0.77 cases/1,000 live birth in 2005–2008 and an estimated 0.21 cases/1,000 live births in 2015 (111, 150, 151). However, while 87% of women in the US undergo cultures to screen for GBS, only an estimated 36% of women in 2016 received care fully compliant to intrapartum antibiotic prophylaxis guidelines; challenges relate to appropriate timing of

screening culture collection, appropriateness of intrapartum antibiotic selection, and appropriateness of intrapartum antibiotic dosages and timing (152).

An alternative strategy, undergoing development, to prevent neonatal and maternal GBS disease is vaccination of mothers in the third trimester against GBS. Lower levels of capsular polysaccharide antibodies in mothers of children with invasive GBS disease compared to mothers of healthy infants have been noted since the 1970s (153, 154). Initial trials of unconjugated GBS polysaccharide vaccines elicited moderate serotype antibody responses (155). More robust antibody responses have been elicited with protein-polysaccharide conjugate vaccines using tetanus toxoid and additional surface protein target vaccines, such as Rib and Alpha C (156–158). Multiple GBS vaccine candidates, including a trivalent protein-polysaccharide conjugate vaccine targeting serotypes Ia, Ib, and III, are currently in development (159). Modeling based on 2015 worldwide disease estimates predict that a GBS vaccine with 80% efficacy and 90% maternal coverage could prevent 107,000 infant deaths and stillbirths (160).

Treatment

Streptococcus agalactiae are uniformly regarded to be susceptible *in vitro* to penicillin, although reduced penicillin susceptibility has been detected in isolates from Japan, thought to be secondary to reduced Penicillin-Binding-Protein (PBP) 2X expression (161, 162). However, penicillin G remains the mainstay of treatment for invasive disease. Generally, GBS is susceptible to other beta-lactam antibiotics, including ampicillin, first-, second-, and third-generation cephalosporins, and carbapenems, although the level of activity varies among different agents. In patients who demonstrate an anaphylactic or severe allergy to beta-lactam antimicrobials, alternative therapies include clindamycin, erythromycin, fluoroquinolones, and vancomycin. However, rising levels of GBS resistance to clindamycin, erythromycin, and fluoroquinolones have been noted in a multitude of studies and these antibiotics should only be used for treatment if a penicillin or cephalosporin is not appropriate and susceptibility of the organism has been determined (162–166). Resistance to vancomycin in clinical isolates has been reported (167).

Penicillin G is the first-line treatment for invasive GBS disease in adults (8). The duration of therapy depends on the clinical presentation. Ten days of therapy is generally acceptable for bacteremia, pneumonia, pyelonephritis, and skin/soft tissue infections. Longer durations of treatment are recommended for meningitis (minimum 14 days), and for osteomyelitis, endocarditis and ventriculitis (minimum 4 weeks) (8). The addition of gentamicin for the initial 2 weeks of therapy is recommended for endocarditis (168).

In neonates with presumptive early onset disease, empiric therapy with ampicillin combined with an aminoglycoside is the standard of care (139). Once GBS is isolated, penicillin G monotherapy is recommended for treatment of invasive GBS infection in infants. Recommended dosing of penicillin G for infants up to 7 days of age is 250,000–450,000 units/kg/day and 450,000–500,000 units/kg/day for infants older than 7 days (139). Ten days of appropriate therapy is recommended for uncomplicated bacteremia and 14 days for uncomplicated meningitis, while complicated infections may require a longer duration of

antimicrobial therapy. Septic arthritis or osteomyelitis is treated for 3–4 weeks and at least 4 weeks of therapy is recommended for endocarditis or ventriculitis (139).

References

1. Lancefield RC. 1933 A Serological Differentiation of Human and Other Groups of Hemolytic Streptococci. *J Exp Med* 57:571–595 10.1084/jem.57.4.571. [PubMed: 19870148]
2. Lancefield RC, Hare R. 1935 The Serological Differentiation of Pathogenic and Non-Pathogenic Strains of Hemolytic Streptococci from Parturient Women. *J Exp Med* 61:335–349 10.1084/jem.61.3.335. [PubMed: 19870362]
3. Fry RM. 1938 Fatal Infections by Haemolytic Streptococcus Group B. *Lancet* 1:199–201 10.1016/S0140-6736(00)93202-1.
4. Braunstein H, Tucker EB, Gibson BC. 1969 Identification and significance of Streptococcus agalactiae (Lancefield group B). *Am J Clin Pathol* 51:207–213 10.1093/ajcp/51.2.207. [PubMed: 4885760]
5. Eickhoff TC, Klein JO, Daly AK, Ingall D, Finland M. 1964 Neonatal Sepsis and Other Infections Due to Group B Beta-Hemolytic Streptococci. *N Engl J Med* 271:1221–1228 10.1056/NEJM196412102712401. [PubMed: 14234266]
6. Lazarus JM, Sellers DP, Marine WM. 1965 Meningitis Due to the Group B Beta-Hemolytic Streptococcus. *N Engl J Med* 272:146–147 10.1056/NEJM196501212720308. [PubMed: 14224221]
7. Mannik M, Baringer JR, Stokes J III. 1962 Infections due to group B beta-hemolytic streptococci. Report of three cases and review of the literature. *N Engl J Med* 266:910–913 10.1056/NEJM196205032661803. [PubMed: 14469375]
8. Edwards MS, Baker CJ. 2015 Streptococcus agalactiae (Group B Streptococcus), p 2340–2348. *In* Bennett JEDR, Blaser MJ (ed), Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Updated Edition, 8th ed Saunders, Philadelphia.
9. Slotved HC, Kong F, Lambertsen L, Sauer S, Gilbert GL. 2007 Serotype IX, a Proposed New Streptococcus agalactiae Serotype. *J Clin Microbiol* 45:2929–2936 10.1128/JCM.00117-07. [PubMed: 17634306]
10. Skoff TH, Farley MM, Petit S, Craig AS, Schaffner W, Gershman K, Harrison LH, Lynfield R, Mohle-Boetani J, Zansky S, Albanese BA, Stefonek K, Zell ER, Jackson D, Thompson T, Schrag SJ. 2009 Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990–2007. *Clin Infect Dis* 49:85–92 10.1086/599369. [PubMed: 19480572]
11. Alhazmi A, Hurteau D, Tyrrell GJ. 2016 Epidemiology of Invasive Group B Streptococcal Disease in Alberta, Canada, from 2003 to 2013. *J Clin Microbiol* 54:1774–1781 10.1128/JCM.00355-16. [PubMed: 27098960]
12. Chaiwarith R, Jullaket W, Bunchoo M, Nuntachit N, Sirisanthana T, Supparatpinyo K. 2011 Streptococcus agalactiae in adults at Chiang Mai University Hospital: a retrospective study. *BMC Infect Dis* 11:149 10.1186/1471-2334-11-149. [PubMed: 21612629]
13. Farley MM, Harvey RC, Stull T, Smith JD, Schuchat A, Wenger JD, Stephens DS. 1993 A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. *N Engl J Med* 328:1807–1811 10.1056/NEJM199306243282503. [PubMed: 8502269]
14. Muñoz P, Llancaqueo A, Rodríguez-Créixems M, Peláez T, Martín L, Bouza E. 1997 Group B streptococcus bacteremia in nonpregnant adults. *Arch Intern Med* 157:213–216 10.1001/archinte.1997.00440230087011. [PubMed: 9009979]
15. Schwartz B, Schuchat A, Oxtoby MJ, Cochi SL, Hightower A, Broome CV. 1991 Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta. *JAMA* 266:1112–1114 10.1001/jama.1991.03470080082034. [PubMed: 1865545]
16. Tazi A, Morand PC, Réglier-Poupert H, Dmytruk N, Billoët A, Antona D, Trieu-Cuot P, Poyart C. 2011 Invasive group B streptococcal infections in adults, France (2007–2010). *Clin Microbiol Infect* 17:1587–1589 10.1111/j.1469-0691.2011.03628.x. [PubMed: 21883671]
17. Eskandarian N, Neela V, Ismail Z, Puzi SM, Hamat RA, Desa MN, Nordin SA. 2013 Group B streptococcal bacteremia in a major teaching hospital in Malaysia: a case series of eighteen patients. *Int J Infect Dis* 17:e777–e780 10.1016/j.ijid.2013.01.011. [PubMed: 23453715]

18. Jackson LA, Hilsdon R, Farley MM, Harrison LH, Reingold AL, Plikaytis BD, Wenger JD, Schuchat A. 1995 Risk factors for group B streptococcal disease in adults. *Ann Intern Med* 123:415–420 10.7326/0003-4819-123-6-199509150-00003. [PubMed: 7639440]
19. Amico S, Calvo L, Corrao S. 2017 An “aubergine” in the heart: huge native mitral valve endocarditis caused by *Streptococcus agalactiae*. *Intern Emerg Med* 10.1007/s11739-017-1731-8.
20. Lerner PI, Gopalakrishna KV, Wolinsky E, McHenry MC, Tan JS, Rosenthal M. 1977 Group B streptococcus (*S. agalactiae*) bacteremia in adults: analysis of 32 cases and review of the literature. *Medicine (Baltimore)* 56:457–473 10.1097/00005792-197711000-00001. [PubMed: 335186]
21. Ivanova Georgieva R, García López MV, Ruiz-Morales J, Martínez-Marcos FJ, Lomas JM, Plata A, Noureddine M, Hidalgo-Tenorio C, Reguera JM, De la Torre Lima J, Gálvez Aceval J, Márquez M, de Alarcón A, Andalusian Group for the Study of Cardiovascular Infections of the Andalusian Society of Infectious Diseases SAEI. 2010 *Streptococcus agalactiae* left-sided infective endocarditis. Analysis of 27 cases from a multicentric cohort. *J Infect* 61:54–59 10.1016/j.jinf.2010.04.005. [PubMed: 20417661]
22. Ariyoshi N, Miyamoto K, Bolger DT, Jr. 2016 *Streptococcus agalactiae* mural infective endocarditis in a structurally normal heart. *J Community Hosp Intern Med Perspect* 6:31113 10.3402/jchimp.v6.31113. [PubMed: 27124171]
23. Fujita H, Nakamura I, Tsukimori A, Sato A, Ohkusu K, Matsumoto T. 2015 Severe infective endocarditis in a healthy adult due to *Streptococcus agalactiae*. *Int J Infect Dis* 38:43–45 10.1016/j.ijid.2015.07.009. [PubMed: 26188131]
24. Edwards MS, Baker CJ. 2005 Group B streptococcal infections in elderly adults. *Clin Infect Dis* 41:839–847 10.1086/432804. [PubMed: 16107984]
25. Sendi P, Johansson L, Norrby-Teglund A. 2008 Invasive group B Streptococcal disease in non-pregnant adults : a review with emphasis on skin and soft-tissue infections. *Infection* 36:100–111 10.1007/s15010-007-7251-0. [PubMed: 18193384]
26. Camuset G, Picot S, Jaubert J, Borgherini G, Ferdynus C, Foucher A, Maïza JC, Fels O, Poyart C, Poubeau P, Gérardin P. 2015. Invasive Group B Streptococcal Disease in Non-pregnant Adults, Réunion Island, 2011. *Int J Infect Dis* 35:46–50 10.1016/j.ijid.2015.04.006. [PubMed: 25892248]
27. García-Lechuz JM, Bachiller P, Vassallo FJ, Muñoz P, Padilla B, Bouza E. 1999 Group B streptococcal osteomyelitis in adults. *Medicine (Baltimore)* 78:191–199 10.1097/00005792-199905000-00005. [PubMed: 10352650]
28. Nolla JM, Gómez-Vaquero C, Corbella X, Ordóñez S, García-Gómez C, Pérez A, Cabo J, Valverde J, Ariza J. 2003 Group B streptococcus (*Streptococcus agalactiae*) pyogenic arthritis in nonpregnant adults. *Medicine (Baltimore)* 82:119–128 10.1097/00005792-200303000-00006. [PubMed: 12640188]
29. Louthrenoo W, Kasitanon N, Wangkaew S, Hongsongkiat S, Sukitawut W, Wichainun R. 2014 *Streptococcus agalactiae*: an emerging cause of septic arthritis. *J Clin Rheumatol* 20:74–78 10.1097/RHU.000000000000071. [PubMed: 24561409]
30. Sendi P, Christensson B, Uçkay I, Trampuz A, Achermann Y, Boggian K, Svensson D, Widerström M, Zimmerli W, GBS PJI study group. 2011 Group B streptococcus in prosthetic hip and knee joint-associated infections. *J Hosp Infect* 79:64–69 10.1016/j.jhin.2011.04.022. [PubMed: 21764170]
31. Corvec S, Illiaquer M, Touchais S, Boutoille D, van der Mee-Marquet N, Quentin R, Reynaud A, Lepelletier D, Bémer P, Bone and Joint Infection Study Group. 2011. Clinical features of group B *Streptococcus* prosthetic joint infections and molecular characterization of isolates. *J Clin Microbiol* 49:380–382 10.1128/JCM.00581-10. [PubMed: 21068273]
32. Zeller V, Lavigne M, Leclerc P, Lhotellier L, Graff W, Ziza JM, Desplaces N, Mamoudy P. 2009 Group B streptococcal prosthetic joint infections: a retrospective study of 30 cases. *Presse Med* 38:1577–1584 10.1016/j.lpm.2009.02.026. [PubMed: 19525087]
33. Verghese A, Berk SL, Boelen LJ, Smith JK. 1982 Group b Streptococcal pneumonia in the elderly. *Arch Intern Med* 142:1642–1645 10.1001/archinte.1982.00340220056012. [PubMed: 7052006]
34. Farley MM. 1995 Group B streptococcal infection in older patients. Spectrum of disease and management strategies. *Drugs Aging* 6:293–300 10.2165/00002512-199506040-00004. [PubMed: 7613018]

35. Skolnik K, Nguyen A, Thornton CS, Waddell B, Williamson T, Rabin HR, Parkins MD. 2017 Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis? *BMC Infect Dis* 17:660 10.1186/s12879-017-2729-6. [PubMed: 28969684]
36. Madrid L, Seale AC, Kohli-Lynch M, Edmond KM, Lawn JE, Heath PT, Madhi SA, Baker CJ, Bartlett L, Cutland C, Gravett MG, Ip M, Le Doare K, Rubens CE, Saha SK, Sobanjo-Ter Meulen A, Vekemans J, Schrag S, Agarwal R, da Silva ARA, Bassat Q, Berkley JA, Dangor Z, Dhaded S, Giannoni E, Hammoud M, Kobayashi M, O'Sullivan C, Sakata H, Sridhar S, Sigauque B, Tyrrell G, Paul V, Infant GBS Disease Investigator Group. 2017 Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-analyses. *Clin Infect Dis* 65(suppl_2):S160–S172 10.1093/cid/cix656. [PubMed: 29117326]
37. Libster R, Edwards KM, Levent F, Edwards MS, Rench MA, Castagnini LA, Cooper T, Sparks RC, Baker CJ, Shah PE. 2012 Long-term outcomes of group B streptococcal meningitis. *Pediatrics* 130:e8–e15 10.1542/peds.2011-3453. [PubMed: 22689869]
38. Kohli-Lynch M, Russell NJ, Seale AC, Dangor Z, Tann CJ, Baker CJ, Bartlett L, Cutland C, Gravett MG, Heath PT, Ip M, Le Doare K, Madhi SA, Rubens CE, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, O'Sullivan C, Nakwa F, Ben Hamouda H, Soua H, Giorgakoudi K, Ladhani S, Lamagni T, Rattue H, Trotter C, Lawn JE. 2017 Neurodevelopmental Impairment in Children After Group B Streptococcal Disease Worldwide: Systematic Review and Meta-analyses. *Clin Infect Dis* 65(suppl_2):S190–S199 10.1093/cid/cix663. [PubMed: 29117331]
39. Ulett KB, Benjamin WH, Jr, Zhuo F, Xiao M, Kong F, Gilbert GL, Schembri MA, Ulett GC. 2009 Diversity of group B streptococcus serotypes causing urinary tract infection in adults. *J Clin Microbiol* 47:2055–2060 10.1128/JCM.00154-09. [PubMed: 19439533]
40. Skerk V, Schönwald S, Krhen I, Markovinovi L, Beus A, Kuzmanovi NS, Kruzi V, Vince A. 2002 Aetiology of chronic prostatitis. *Int J Antimicrob Agents* 19:471–474 10.1016/S0924-8579(02)00087-0. [PubMed: 12135835]
41. Pérez-Moreno MO, Picó-Plana E, Grande-Armas J, Centelles-Serrano MJ, Arasa-Subero M, Ochoa NC, Led By Mo Pérez-Moreno MOTSGG. 2017 Group B streptococcal bacteriuria during pregnancy as a risk factor for maternal intrapartum colonization: a prospective cohort study. *J Med Microbiol* 66:454–460 10.1099/jmm.0.000465. [PubMed: 28463661]
42. Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). 2010 Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. *MMWR Recomm Rep* 59(RR-10):1–36.
43. Deutscher M, Lewis M, Zell ER, Taylor TH, Jr, Van Beneden C, Schrag S, Active Bacterial Core Surveillance Team. 2011 Incidence and severity of invasive *Streptococcus pneumoniae*, group A *Streptococcus*, and group B *Streptococcus* infections among pregnant and postpartum women. *Clin Infect Dis* 53:114–123 10.1093/cid/cir325. [PubMed: 21690617]
44. Hall J, Adams NH, Bartlett L, Seale AC, Lamagni T, Bianchi-Jassir F, Lawn JE, Baker CJ, Cutland C, Heath PT, Ip M, Le Doare K, Madhi SA, Rubens CE, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Gravett MG. 2017 Maternal Disease With Group B *Streptococcus* and Serotype Distribution Worldwide: Systematic Review and Meta-analyses. *Clin Infect Dis* 65(suppl_2):S112–S124 10.1093/cid/cix660. [PubMed: 29117328]
45. Zaleznik DF, Rench MA, Hillier S, Krohn MA, Platt R, Lee ML, Flores AE, Ferrieri P, Baker CJ. 2000 Invasive disease due to group B *Streptococcus* in pregnant women and neonates from diverse population groups. *Clin Infect Dis* 30:276–281 10.1086/313665. [PubMed: 10671328]
46. Cho CY, Tang YH, Chen YH, Wang SY, Yang YH, Wang TH, Yeh CC, Wu KG, Jeng MJ. 2017. Group B *Streptococcal* infection in neonates and colonization in pregnant women: an epidemiological retrospective analysis. *J Microbiol Immunol Infect* 1684–1182(17)30185–8 10.1016/j.jmii.2017.08.004.
47. Lee BK, Song YR, Kim MY, Yang JH, Shin JH, Seo YS, Oh KY, Yoon HR, Pai SY, Foxman B, Ki M. 2010 Epidemiology of group B streptococcus in Korean pregnant women. *Epidemiol Infect* 138:292–298 10.1017/S0950268809990859. [PubMed: 19781117]
48. Lee WT, Lai MC. 2015 High prevalence of *Streptococcus agalactiae* from vaginas of women in Taiwan and its mechanisms of macrolide and quinolone resistance. *J Microbiol Immunol Infect* 48:510–516 10.1016/j.jmii.2014.03.002. [PubMed: 24767417]

49. Ji W, Zhang L, Guo Z, Xie S, Yang W, Chen J, Wang J, Cheng Z, Wang X, Zhu X, Wang J, Wang H, Huang J, Liang N, McIver DJ. 2017 Colonization prevalence and antibiotic susceptibility of Group B Streptococcus in pregnant women over a 6-year period in Dongguan, China. *PLoS One* 12:e0183083 10.1371/journal.pone.0183083. [PubMed: 28813477]
50. Lu B, Li D, Cui Y, Sui W, Huang L, Lu X. 2014 Epidemiology of Group B streptococcus isolated from pregnant women in Beijing, China. *Clin Microbiol Infect* 20:O370–O373 10.1111/1469-0691.12416. [PubMed: 24118553]
51. Xie Y, Yang J, Zhao P, Jia H, Wang Q. 2016 Occurrence and detection method evaluation of group B streptococcus from prenatal vaginal specimen in Northwest China. *Diagn Pathol* 11:8 10.1186/s13000-016-0463-9. [PubMed: 26791082]
52. Alemseged G, Niguse S, Hailekiros H, Abdulkadir M, Saravanan M, Asmelash T. 2015 Isolation and anti-microbial susceptibility pattern of group B Streptococcus among pregnant women attending antenatal clinics in Ayder Referral Hospital and Mekelle Health Center, Mekelle, Northern Ethiopia. *BMC Res Notes* 8:518 10.1186/s13104-015-1475-3. [PubMed: 26428867]
53. Mengist A, Kannan H, Abdissa A. 2016 Prevalence and antimicrobial susceptibility pattern of anorectal and vaginal group B Streptococci isolates among pregnant women in Jimma, Ethiopia. *BMC Res Notes* 9:351 10.1186/s13104-016-2158-4. [PubMed: 27435469]
54. Mengist HM, Zewdie O, Belew A, Dabsu R. 2017 Prevalence and drug susceptibility pattern of group B Streptococci (GBS) among pregnant women attending antenatal care (ANC) in Nekemte Referral Hospital (NRH), Nekemte, Ethiopia. *BMC Res Notes* 10:388 10.1186/s13104-017-2725-3. [PubMed: 28797286]
55. Emaneini M, Jabalameli F, van Leeuwen WB, Beigverdi R. 2017 Prevalence of Group B Streptococcus in Pregnant Women in Iran: A Systematic Review and Meta-Analysis. *Pediatr Infect Dis J* 10.1097/INF.0000000000001713.
56. Goudarzi G, Ghafarzadeh M, Shakib P, Anbari K. 2015 Culture and Real-Time PCR Based Maternal Screening and Antibiotic Susceptibility for Group B Streptococcus: an Iranian Experience. *Glob J Health Sci* 7:233–239 10.5539/gjhs.v7n6p233.
57. Hadavand S, Ghafoorimehr F, Rajabi L, Davati A, Zafarghandi N. 2015 Frequency of Group B Streptococcal Colonization in Pregnant Women Aged 35– 37 Weeks in Clinical Centers of Shahed University, Tehran, Iran. *Iran J Pathol* 10:120–126. [PubMed: 26351472]
58. Hamed A, Akhlaghi F, Seyedi SJ, Kharazmi A. 2012 Evaluation of group B Streptococci colonization rate in pregnant women and their newborn. *Acta Med Iran* 50:805–808. [PubMed: 23456521]
59. Hassanzadeh P, Motamedifar M, Gharaghani MN. 2011 Carriage rate of group B streptococci in pregnant women in three teaching hospitals in Shiraz, Iran. *Med Princ Pract* 20:277–282 10.1159/000323754. [PubMed: 21455000]
60. Javanmanesh F, Eshraghi N. 2013 Prevalence of positive recto-vaginal culture for Group B streptococcus in pregnant women at 35–37 weeks of gestation. *Med J Islam Repub Iran* 27:7–11. [PubMed: 23483827]
61. Slotved HC, Dayie NTKD, Banini JAN, Frimodt-Møller N. 2017 Carriage and serotype distribution of Streptococcus agalactiae in third trimester pregnancy in southern Ghana. *BMC Pregnancy Childbirth* 17:238 10.1186/s12884-017-1419-0. [PubMed: 28732495]
62. Vinnemeier CD, Brust P, Owusu-Dabo E, Sarpong N, Sarfo EY, Bio Y, Rolling T, Dekker D, Adu-Sarkodie Y, Eberhardt KA, May J, Cramer JP. 2015 Group B Streptococci serotype distribution in pregnant women in Ghana: assessment of potential coverage through future vaccines. *Trop Med Int Health* 20:1516–1524 10.1111/tmi.12589. [PubMed: 26285044]
63. Khalil MR, Uldbjerg N, Thorsen PB, Møller JK. 2017 Intrapartum PCR assay versus antepartum culture for assessment of vaginal carriage of group B streptococci in a Danish cohort at birth. *PLoS One* 12:e0180262 10.1371/journal.pone.0180262. [PubMed: 28678829]
64. Petersen KB, Johansen HK, Rosthøj S, Krebs L, Pinborg A, Hedegaard M. 2014 Increasing prevalence of group B streptococcal infection among pregnant women. *Dan Med J* 61:A4908. [PubMed: 25186546]

65. Chan GJ, Modak JK, Mahmud AA, Baqui AH, Black RE, Saha SK. 2013 Maternal and neonatal colonization in Bangladesh: prevalences, etiologies and risk factors. *J Perinatol* 33:971–976 10.1038/jp.2013.99. [PubMed: 23989196]
66. Saha SK, Ahmed ZB, Modak JK, Naziat H, Saha S, Uddin MA, Islam M, Baqui AH, Darmstadt GL, Schrag SJ. 2017 Group B Streptococcus among Pregnant Women and Newborns in Mirzapur, Bangladesh: Colonization, Vertical Transmission, and Serotype Distribution. *J Clin Microbiol* 55:2406–2412 10.1128/JCM.00380-17. [PubMed: 28515218]
67. Rick AM, Aguilar A, Cortes R, Gordillo R, Melgar M, Samayoa-Reyes G, Frank DN, Asturias EJ. 2017 Group B Streptococci Colonization in Pregnant Guatemalan Women: Prevalence, Risk Factors, and Vaginal Microbiome. *Open Forum Infect Dis* 4:ofx020 10.1093/ofid/ofx020. [PubMed: 28480290]
68. Elikwu CJ, Oduyebo O, Ogunsola FT, Anorlu RI, Okoromah CN, König B. 2016 High group B streptococcus carriage rates in pregnant women in a tertiary institution in Nigeria. *Pan Afr Med J* 25:249 10.11604/pamj.2016.25.249.9433. [PubMed: 28293365]
69. Chaudhary M, Rench MA, Baker CJ, Singh P, Hans C, Edwards MS. 2017 Group B Streptococcal Colonization Among Pregnant Women in DelhiIndia. *J Pediatr Infect Dis J* 36:665–669 10.1097/INF.0000000000001514. [PubMed: 28027278]
70. Sharmila V, Joseph NM, Arun Babu T, Chaturvedula L, Sistla S. 2011 Genital tract group B streptococcal colonization in pregnant women: a South Indian perspective. *J Infect Dev Ctries* 5:592–595. [PubMed: 21841303]
71. Matani C, Trezzi M, Matteini A, Catalani C, Messeri D, Catalani C. 2016 Streptococcus agalactiae: prevalence of antimicrobial resistance in vaginal and rectal swabs in Italian pregnant women. *Infez Med* 24:217–221. [PubMed: 27668902]
72. Puccio G, Cajozzo C, Canduscio LA, Cino L, Romano A, Schimmenti MG, Giuffrè M, Corsello G. 2014 Epidemiology of Toxoplasma and CMV serology and of GBS colonization in pregnancy and neonatal outcome in a Sicilian population. *Ital J Pediatr* 40:23 10.1186/1824-7288-40-23. [PubMed: 24559197]
73. Kunze M, Ziegler A, Fluegge K, Hentschel R, Proempeler H, Berner R. 2011 Colonization, serotypes and transmission rates of group B streptococci in pregnant women and their infants born at a single University Center in Germany. *J Perinat Med* 39:417–422 10.1515/jpm.2011.037. [PubMed: 21557677]
74. Namugongo A, Bazira J, Fajardot Y, Joseph N. 2016 Group B Streptococcus Colonization among Pregnant Women Attending Antenatal Care at Tertiary Hospital in Rural Southwestern Uganda. *Int J Microbiol* 2016:3816184 10.1155/2016/3816184. [PubMed: 27313620]
75. Alp F, Findik D, Dagi HT, Arslan U, Pekin AT, Yilmaz SA. 2016 Screening and genotyping of group B streptococcus in pregnant and non-pregnant women in Turkey. *J Infect Dev Ctries* 10:222–226 10.3855/jidc.6190. [PubMed: 27031453]
76. Chaudhry BY, Akhtar N, Balouch AH. 2010 Vaginal carriage rate of group B Streptococcus in pregnant women and its transmission to neonates. *J Ayub Med Coll Abbottabad* 22:167–170.
77. Munir SI, Waheed K, Khanum A, Iqbal R, Eusaph AZ, Hanif A. 2016 Frequency of Group B Streptococci in Pregnant Women in a Tertiary Care Hospital. *J Coll Physicians Surg Pak* 26:27–30. [PubMed: 26787027]
78. Khan MA, Faiz A, Ashshi AM. 2015 Maternal colonization of group B streptococcus: prevalence, associated factors and antimicrobial resistance. *Ann Saudi Med* 35:423–427 10.5144/0256-4947.2015.423. [PubMed: 26657224]
79. Mitima KT, Ntamako S, Birindwa AM, Mukanire N, Kivukuto JM, Tsongo K, Mubagwa K. 2014 Prevalence of colonization by Streptococcus agalactiae among pregnant women in Bukavu, Democratic Republic of the Congo. *J Infect Dev Ctries* 8:1195–1200 10.3855/jidc.5030. [PubMed: 25212085]
80. Ghaddar N, Alfouzan W, Anastasiadis E, Al Jiser T, Itani SE, Dernaika R, Eid T, Ghaddar A, Charafeddine A, Dhar R, El Hajj H. 2014 Evaluation of chromogenic medium and direct latex agglutination test for detection of group B streptococcus in vaginal specimens from pregnant women in Lebanon and Kuwait. *J Med Microbiol* 63:1395–1399 10.1099/jmm.0.066738-0. [PubMed: 25082944]

81. Seoud M, Nassar AH, Zalloua P, Boghossian N, Ezeddine J, Fakhoury H, Abboud J, Melki I, Araj G, Nacouzi G, Sanyoura M, Yunis K. 2010 Prenatal and neonatal Group B Streptococcus screening and serotyping in Lebanon: incidence and implications. *Acta Obstet Gynecol Scand* 89:399–403 10.3109/00016340903560008. [PubMed: 20199356]
82. Oviedo P, Pegels E, Laczeski M, Quiroga M, Vergara M. 2013 Phenotypic and genotypic characterization of Streptococcus agalactiae in pregnant women. First study in a province of Argentina. *Braz J Microbiol* 44:253–258 10.1590/S1517-83822013005000030. [PubMed: 24159312]
83. Quiroga M, Pegels E, Oviedo P, Pereyra E, Vergara M. 2008 Antibiotic susceptibility patterns and prevalence of group B Streptococcus isolated from pregnant women in Misiones, Argentina. *Braz J Microbiol* 39:245–250 10.1590/S1517-83822008000200009. [PubMed: 24031210]
84. Brzychczy-Włoch M, Ocho ska D, Bulanda M. 2013 Carriage of group B streptococci in pregnant women from the region of Krakow and their antibiotic resistance in the years 2008–2012. *Pol J Microbiol* 62:427–433. [PubMed: 24730138]
85. Strus M, Pawlik D, Brzychczy-Włoch M, Gosiewski T, Rytlewski K, Lauterbach R, Heczko PB. 2009 Group B streptococcus colonization of pregnant women and their children observed on obstetric and neonatal wards of the University Hospital in Krakow, Poland. *J Med Microbiol* 58:228–233 10.1099/jmm.0.002865-0. [PubMed: 19141741]
86. Turner C, Turner P, Po L, Maner N, De Zoysa A, Afshar B, Efstratiou A, Heath PT, Nosten F. 2012 Group B streptococcal carriage, serotype distribution and antibiotic susceptibilities in pregnant women at the time of delivery in a refugee population on the Thai-Myanmar border. *BMC Infect Dis* 12:34 10.1186/1471-2334-12-34. [PubMed: 22316399]
87. Barcaite E, Bartusevicius A, Tameliene R, Maleckiene L, Vitkauskiene A, Nadisauskiene R. 2012 Group B streptococcus and Escherichia coli colonization in pregnant women and neonates in Lithuania. *Int J Gynaecol Obstet* 117:69–73 10.1016/j.ijgo.2011.11.016. [PubMed: 22265188]
88. Castellano-Filho DS, da Silva VL, Nascimento TC, de Toledo Vieira M, Diniz CG. 2010 Detection of Group B Streptococcus in Brazilian pregnant women and antimicrobial susceptibility patterns. *Braz J Microbiol* 41:1047–1055 10.1590/S1517-83822010000400024. [PubMed: 24031585]
89. Hong JS, Choi CW, Park KU, Kim SN, Lee HJ, Lee HR, Choi EH, Park KH, Suh CS, Kim BI, Choi ST, Kim SS. 2010 Genital group B Streptococcus carrier rate and serotype distribution in Korean pregnant women: implications for group B streptococcal disease in Korean neonates. *J Perinat Med* 38:373–377 10.1515/jpm.2010.050. [PubMed: 20297897]
90. Mavenyengwa RT, Moyo SR, Nordbø SA. 2010 Streptococcus agalactiae colonization and correlation with HIV-1 and HBV seroprevalence in pregnant women from Zimbabwe. *Eur J Obstet Gynecol Reprod Biol* 150:34–38 10.1016/j.ejogrb.2010.02.021. [PubMed: 20189288]
91. Joachim A, Matee MI, Massawe FA, Lyamuya EF. 2009 Maternal and neonatal colonisation of group B streptococcus at Muhimbili National Hospital in Dar es Salaam, Tanzania: prevalence, risk factors and antimicrobial resistance. *BMC Public Health* 9:437 10.1186/1471-2458-9-437. [PubMed: 19948075]
92. Shabayek SA, Abdalla SM, Abouzeid AM. 2009 Vaginal carriage and antibiotic susceptibility profile of group B Streptococcus during late pregnancy in Ismailia, Egypt. *J Infect Public Health* 2:86–90 10.1016/j.jiph.2009.03.004. [PubMed: 20701866]
93. de Steenwinkel FD, Tak HV, Muller AE, Nouwen JL, Oostvogel PM, Mocumbi SM. 2008 Low carriage rate of group B streptococcus in pregnant women in Maputo, Mozambique. *Trop Med Int Health* 13:427–429 10.1111/j.1365-3156.2008.02018.x. [PubMed: 18397403]
94. Centers for Disease Control and Prevention. October 27, 2016. 2016 Group B Strep (GBS). <https://www.cdc.gov/groupbstrep/index.html>. Accessed November 1 2017.
95. Regan JA, Klebanoff MA, Nugent RP, Vaginal Infections and Prematurity Study Group. 1991 The epidemiology of group B streptococcal colonization in pregnancy. *Obstet Gynecol* 77:604–610. [PubMed: 2002986]
96. Campbell JR, Hillier SL, Krohn MA, Ferrieri P, Zaleznik DF, Baker CJ. 2000 Group B streptococcal colonization and serotype-specific immunity in pregnant women at delivery. *Obstet Gynecol* 96:498–503. [PubMed: 11004347]

97. Money D, Allen VM. 2016 The Prevention of Early-Onset Neonatal Group B Streptococcal Disease. *J Obstet Gynaecol Can* 38(12S):S326–S335 10.1016/j.jogc.2016.09.042. [PubMed: 28063544]
98. Russell NJ, Seale AC, O’Driscoll M, O’Sullivan C, Bianchi-Jassir F, Gonzalez-Guarin J, Lawn JE, Baker CJ, Bartlett L, Cutland C, Gravett MG, Heath PT, Le Doare K, Madhi SA, Rubens CE, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Saha SK, Ip M, Group GBSMCI, GBS Maternal Colonization Investigator Group. 2017 Maternal Colonization With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-analyses. *Clin Infect Dis* 65(suppl_2):S100–S111 10.1093/cid/cix658. [PubMed: 29117327]
99. Brzywczy-Włoch M, Pabian W, Majewska E, Zuk MG, Kielbik J, Gosiewski T, Bulanda MG. 2014 Dynamics of colonization with group B streptococci in relation to normal flora in women during subsequent trimesters of pregnancy. *New Microbiol* 37:307–319. [PubMed: 25180845]
100. Bianchi-Jassir F, Seale AC, Kohli-Lynch M, Lawn JE, Baker CJ, Bartlett L, Cutland C, Gravett MG, Heath PT, Ip M, Le Doare K, Madhi SA, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Rubens CE. 2017 Preterm Birth Associated With Group B Streptococcus Maternal Colonization Worldwide: Systematic Review and Meta-analyses. *Clin Infect Dis* 65(suppl_2):S133–S142 10.1093/cid/cix661. [PubMed: 29117329]
101. Colicchia LC, Lauderdale DS, Du H, Adams M, Hirsch E. 2015 Recurrence of group B streptococcus colonization in successive pregnancies. *J Perinatol* 35:173–176 10.1038/jp.2014.185. [PubMed: 25321646]
102. Turrentine MA, Colicchia LC, Hirsch E, Cheng PJ, Tam T, Ramsey PS, Page-Ramsey SM. 2016 Efficiency of Screening for the Recurrence of Antenatal Group B Streptococcus Colonization in a Subsequent Pregnancy: A Systematic Review and Meta-analysis with Independent Patient Data. *Am J Perinatol* 33:510–517. [PubMed: 26683604]
103. Rosen GH, Randis TM, Desai PV, Sapra KJ, Ma B, Gajer P, Humphrys MS, Ravel J, Gelber SE, Ratner AJ. 2017 Group B Streptococcus and the Vaginal Microbiota. *J Infect Dis* 216:744–751 10.1093/infdis/jix395. [PubMed: 28934437]
104. Ho M, Chang YY, Chang WC, Lin HC, Wang MH, Lin WC, Chiu TH. 2016 Oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 to reduce Group B Streptococcus colonization in pregnant women: A randomized controlled trial. *Taiwan J Obstet Gynecol* 55:515–518 10.1016/j.tjog.2016.06.003. [PubMed: 27590374]
105. Olsen P, Williamson M, Traynor V, Georgiou C. 2017 The impact of oral probiotics on vaginal Group B Streptococcal colonisation rates in pregnant women: A pilot randomised control study. *Women Birth* 10.1016/j.wombi.2017.06.012.
106. Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S, Craig AS, Schaffner W, Zansky SM, Gershman K, Stefonek KR, Albanese BA, Zell ER, Schuchat A, Schrag SJ, Active Bacterial Core surveillance/Emerging Infections Program Network. 2008 Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. *JAMA* 299:2056–2065 10.1001/jama.299.17.2056. [PubMed: 18460666]
107. Kothari NJ, Morin CA, Glennen A, Jackson D, Harper J, Schrag SJ, Lynfield R. 2009 Invasive group B streptococcal disease in the elderly, Minnesota, USA, 2003–2007. *Emerg Infect Dis* 15:1279–1281 10.3201/eid1508.081381. [PubMed: 19751591]
108. Tyrrell GJ, Senzilet LD, Spika JS, Kertesz DA, Alagaratnam M, Lovgren M, Talbot JA, Sentinel Health Unit Surveillance System Site Coordinators. 2000 Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study—1996. *J Infect Dis* 182:168–173 10.1086/315699. [PubMed: 10882594]
109. Lamagni TL, Keshishian C, Efstratiou A, Guy R, Henderson KL, Broughton K, Sheridan E. 2013 Emerging trends in the epidemiology of invasive group B streptococcal disease in England and Wales, 1991–2010. *Clin Infect Dis* 57:682–688 10.1093/cid/cit337. [PubMed: 23845950]
110. Trivalle C, Martin E, Martel P, Jacque B, Menard JF, Lemeland JF. 1998 Group B streptococcal bacteraemia in the elderly. *J Med Microbiol* 47:649–652 10.1099/00222615-47-7-649. [PubMed: 9839570]
111. Centers for Disease Control and Prevention. 2015 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2015. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs15.pdf>.

112. Kaplan EL, Johnson DR, Kuritsky JN. 1983 Rectal colonization by group B beta-hemolytic streptococci in a geriatric population. *J Infect Dis* 148:1120 10.1093/infdis/148.6.1120. [PubMed: 6361172]
113. Ballard MS, Schønheyder HC, Knudsen JD, Lyytikäinen O, Dryden M, Kennedy KJ, Valiquette L, Pinholt M, Jacobsson G, Laupland KB, International Bacteremia Surveillance Collaborative. 2016 The changing epidemiology of group B streptococcus bloodstream infection: a multi-national population-based assessment. *Infect Dis (Lond)* 48:386–391 10.3109/23744235.2015.1131330. [PubMed: 26759190]
114. Schrag SJ, Farley MM, Petit S, Reingold A, Weston EJ, Pondo T, Hudson Jain J, Lynfield R. 2016 Epidemiology of Invasive Early-Onset Neonatal Sepsis, 2005 to 2014. *Pediatrics* 138:138 10.1542/peds.2016-2013.
115. Stoll BJ, Hansen NI, Sánchez PJ, Faix RG, Poindexter BB, Van Meurs KP, Bizzarro MJ, Goldberg RN, Frantz ID III, Hale EC, Shankaran S, Kennedy K, Carlo WA, Watterberg KL, Bell EF, Walsh MC, Schibler K, Laptook AR, Shane AL, Schrag SJ, Das A, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. 2011 Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. *Pediatrics* 127:817–826 10.1542/peds.2010-2217. [PubMed: 21518717]
116. Centers for Disease Control and Prevention. 2014 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2014. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs14.pdf>.
117. Centers for Disease Control and Prevention. 2013 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2013.
118. Centers for Disease Control and Prevention. 2013 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2012. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs12.pdf>.
119. Centers for Disease Control and Prevention. 2012 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2011. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs11.pdf>.
120. Centers for Disease Control and Prevention. 2012 *Active* Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2010. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs10.pdf>.
121. Centers for Disease Control and Prevention. 2010 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2009. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs09.pdf>.
122. Centers for Disease Control and Prevention. 2009 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2008. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs08.pdf>.
123. Centers for Disease Control and Prevention. 2008 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2007. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs07.pdf>.
124. Centers for Disease Control and Prevention. 2008 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2006. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs06.pdf>.
125. Centers for Disease Control and Prevention. 2006 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2005. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs05.pdf>.
126. Centers for Disease Control and Prevention. 2005 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2004. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs04.pdf>.
127. Centers for Disease Control and Prevention. 2004 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2003. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs03.pdf>.

128. Centers for Disease Control and Prevention. 2003 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2002. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs02.pdf>.
129. Centers for Disease Control and Prevention. 2002 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2001. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs01.pdf>.
130. Centers for Disease Control and Prevention. 2002 Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, group B streptococcus, 2000. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs00.pdf>.
131. Centers for Disease Control and Prevention. 2000 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 1999. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs99.pdf>.
132. Centers for Disease Control and Prevention. 1999 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 1998. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs98.pdf>.
133. Centers for Disease Control and Prevention. 1998 Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 1997. <https://www.cdc.gov/abcs/reports-findings/survreports/gbs97.pdf>.
134. Tann CJ, Martinello KA, Sadoo S, Lawn JE, Seale AC, Vega-Poblete M, Russell NJ, Baker CJ, Bartlett L, Cutland C, Gravett MG, Ip M, Le Doare K, Madhi SA, Rubens CE, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Heath PT, Garcia-Alix A, Boo N- Y, Martinez-Biarge M, Cheong J, Cowan F, de Vries LS, Arca-Diaz G, Edwards AD, Ellis M, Gale C, Glass HC, Groenendaal F, Gunn A, Hayes B, Jacobs SE, Johnson CT, Kali G, Manne M, Massaro AN, Robertson NJ, Shah P, Shankaran S, Tann CJ, Thayyil S, Thoresen M, Walsh BH, Wintermark P, Lee ACC, GBS Neonatal Encephalopathy Investigator Group. 2017 Neonatal Encephalopathy With Group B Streptococcal Disease Worldwide: Systematic Review, Investigator Group Datasets, and Meta-analysis. *Clin Infect Dis* 65(suppl_2):S173–S189 10.1093/cid/cix662. [PubMed: 29117330]
135. Rivera L, Sáez-Llorens X, Feris-Iglesias J, Ip M, Saha S, Adrian PV, Madhi SA, Boudville IC, Cunnington MC, Casellas JM, Slobod KS. 2015 Incidence and serotype distribution of invasive group B streptococcal disease in young infants: a multi-country observational study. *BMC Pediatr* 15:143 10.1186/s12887-015-0460-2. [PubMed: 26427955]
136. Quan V, Verani JR, Cohen C, von Gottberg A, Meiring S, Cutland CL, Schrag SJ, Madhi SA. 2016 Invasive Group B Streptococcal Disease in South Africa: Importance of Surveillance Methodology. *PLoS One* 11:e0152524 10.1371/journal.pone.0152524. [PubMed: 27055184]
137. Matsubara K, Hoshina K, Kondo M, Miyairi I, Yukitake Y, Ito Y, Minami K, Genkawa R. 2017 Group B streptococcal disease in infants in the first year of life: a nationwide surveillance study in Japan, 2011–2015. *Infection* 45:449–458 10.1007/s15010-017-0995-2. [PubMed: 28236250]
138. Berardi A, Rossi C, Lugli L, Creti R, Bacchi Reggiani ML, Lanari M, Memo L, Pedna MF, Venturelli C, Perrone E, Ciccio M, Tridapalli E, Piepoli M, Contiero R, Ferrari F, GBS Prevention Working Group, Emilia-Romagna. 2013 Group B streptococcus late-onset disease: 2003–2010. *Pediatrics* 131:e361–e368 10.1542/peds.2012-1231. [PubMed: 23296441]
139. Kimberlin DW, Brady MT, Jackson MA, Long SS(ed).2015 Red Book, 30th Edition (2015).
140. Cools P, van de Wijgert JHHM, Jaspers V, Crucitti T, Sanders EJ, Verstraelen H, Vanechoutte M. 2017 Role of HIV exposure and infection in relation to neonatal GBS disease and rectovaginal GBS carriage: a systematic review and meta-analysis. *Sci Rep* 7:13820 10.1038/s41598-017-13218-1. [PubMed: 29062060]
141. Lin FY, Weisman LE, Troendle J, Adams K. 2003 Prematurity is the major risk factor for late-onset group B streptococcus disease. *J Infect Dis* 188:267–271 10.1086/376457. [PubMed: 12854082]
142. Baker CJ. 1977 Summary of the workshop on perinatal infections due to group B Streptococcus. *J Infect Dis* 136:137–152 10.1093/infdis/136.1.137. [PubMed: 69669]
143. Arias-Camison JM. 2003 Late onset group B streptococcal infection from maternal expressed breast milk in a very low birth weight infant. *J Perinatol* 23:691–692 10.1038/sj.jp.7210994. [PubMed: 14647171]

144. Seale AC, Blencowe H, Bianchi-Jassir F, Embleton N, Bassat Q, Ordi J, Menéndez C, Cutland C, Briner C, Berkley JA, Lawn JE, Baker CJ, Bartlett L, Gravett MG, Heath PT, Ip M, Le Doare K, Rubens CE, Saha SK, Schrag S, Meulen AS, Vekemans J, Madhi SA. 2017 Stillbirth With Group B Streptococcus Disease Worldwide: Systematic Review and Meta-analyses. *Clin Infect Dis* 65(suppl_2):S125–S132 10.1093/cid/cix585. [PubMed: 29117322]
145. Franciosi RA, Knostman JD, Zimmerman RA. 1973 Group B streptococcal neonatal and infant infections. *J Pediatr* 82:707–718 10.1016/S0022-3476(73)80604-3. [PubMed: 4572747]
146. Russell NJ, Seale AC, O’Sullivan C, Le Doare K, Heath PT, Lawn JE, Bartlett L, Cutland C, Gravett M, Ip M, Madhi SA, Rubens CE, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Baker CJ. 2017 Risk of Early-Onset Neonatal Group B Streptococcal Disease With Maternal Colonization Worldwide: Systematic Review and Meta-analyses. *Clin Infect Dis* 65(suppl_2):S152–S159 10.1093/cid/cix655. [PubMed: 29117325]
147. Le Doare K, O’Driscoll M, Turner K, Seedat F, Russell NJ, Seale AC, Heath PT, Lawn JE, Baker CJ, Bartlett L, Cutland C, Gravett MG, Ip M, Madhi SA, Rubens CE, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Kampmann B, Ramoni A, Helmig RB, Makikallio K, Asatiani T, Fisher M, Feinstein M, Oz Y, Suzin ME, Eisenberg V, Berardi A, Trehan I, Macad GL, Lucovnik M, Oluwalana CN, Letchworth P, Jagoutz-Herzlinger M, Muriithi FG, Yassen KI, Visser G, Cooper S, GBS Intrapartum Antibiotic Investigator Group. 2017 Intrapartum Antibiotic Chemoprophylaxis Policies for the Prevention of Group B Streptococcal Disease Worldwide: systematic Review. *Clin Infect Dis* 65(suppl_2):S143–S151 10.1093/cid/cix654. [PubMed: 29117324]
148. Hughes RGBP, Steer PJ, Heath P. 2017 Prevention of early-onset neonatal group B streptococcal disease. Green-top Guideline No. 36. *BJOG* 124:e280–e305 10.1111/1471-0528.14821. [PubMed: 28901693]
149. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. 2016 Maternal Group B Streptococcus in pregnancy: screening and management.
150. Centers for Disease Control and Prevention (CDC). 1997 Decreasing incidence of perinatal Group B streptococcal disease--United States, 1993–1995. *MMWR Morb Mortal Wkly Rep* 46:473–477. [PubMed: 9182211]
151. Weston EJ, Pondo T, Lewis MM, Martell-Cleary P, Morin C, Jewell B, Daily P, Apostol M, Petit S, Farley M, Lynfield R, Reingold A, Hansen NI, Stoll BJ, Shane AL, Zell E, Schrag SJ. 2011 The burden of invasive early-onset neonatal sepsis in the United States, 2005–2008. *Pediatr Infect Dis J* 30:937–941 10.1097/INF.0b013e318223bad2. [PubMed: 21654548]
152. Bianco A, Larosa E, Pileggi C, Pavia M, Collaborative Working Group. 2016 Appropriateness of Intrapartum Antibiotic Prophylaxis to Prevent Neonatal Group B Streptococcus Disease. *PLoS One* 11:e0166179 10.1371/journal.pone.0166179. [PubMed: 27861568]
153. Baker CJ, Kasper DL. 1976 Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. *N Engl J Med* 294:753–756 10.1056/NEJM197604012941404. [PubMed: 768760]
154. Dangor Z, Kwatra G, Izu A, Lala SG, Madhi SA. 2015 Review on the association of Group B Streptococcus capsular antibody and protection against invasive disease in infants. *Expert Rev Vaccines* 14:135–149 10.1586/14760584.2014.953939. [PubMed: 25242617]
155. Baker CJ, Kasper DL. 1985 Group B streptococcal vaccines. *Rev Infect Dis* 7:458–467 10.1093/clinids/7.4.458. [PubMed: 3898306]
156. Baker CJ, Rench MA, McInnes P. 2003 Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. *Vaccine* 21:3468–3472 10.1016/S0264-410X(03)00353-0. [PubMed: 12850362]
157. Larsson C, Stålhammar-Carlemalm M, Lindahl G. 1999 Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine. *Vaccine* 17:454–458 10.1016/S0264-410X(98)00218-7. [PubMed: 10073723]
158. Heath PT. 2011 An update on vaccination against group B streptococcus. *Expert Rev Vaccines* 10:685–694 10.1586/erv.11.61. [PubMed: 21604988]
159. Heath PT. 2016. Status of vaccine research and development of vaccines for GBS. *Vaccine* 34:2876–2879 10.1016/j.vaccine.2015.12.072. [PubMed: 26988258]

160. Seale AC, Bianchi-Jassir F, Russell NJ, Kohli-Lynch M, Tann CJ, Hall J, Madrid L, Blencowe H, Cousens S, Baker CJ, Bartlett L, Cutland C, Gravett MG, Heath PT, Ip M, Le Doare K, Madhi SA, Rubens CE, Saha SK, Schrag SJ, Sobanjo-Ter Meulen A, Vekemans J, Lawn JE. 2017 Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children. *Clin Infect Dis* 65(suppl_2):S200–S219 10.1093/cid/cix664. [PubMed: 29117332]
161. Kimura K, Nishiyama Y, Shimizu S, Wachino J, Matsui M, Suzuki S, Yamane K, Shibayama K, Arakawa Y. 2013 Screening for group B streptococci with reduced penicillin susceptibility in clinical isolates obtained between 1977 and 2005. *Jpn J Infect Dis* 66:222–225 10.7883/yoken.66.222. [PubMed: 23698483]
162. Seki T, Kimura K, Reid ME, Miyazaki A, Banno H, Jin W, Wachino J, Yamada K, Arakawa Y. 2015 High isolation rate of MDR group B streptococci with reduced penicillin susceptibility in Japan. *J Antimicrob Chemother* 70:2725–2728 10.1093/jac/dkv203. [PubMed: 26169560]
163. Hawkins PA, Law CS, Metcalf BJ, Chochua S, Jackson DM, Westblade LF, Jerriss R, Beall BW, McGee L. 2017 Cross-resistance to lincosamides, streptogramins A and pleuromutilins in *Streptococcus agalactiae* isolates from the USA. *J Antimicrob Chemother* 72:1886–1892 10.1093/jac/dkx077. [PubMed: 28333320]
164. Wehbeh W, Rojas-Diaz R, Li X, Mariano N, Grenner L, Segal-Maurer S, Tommasulo B, Drlica K, Urban C, Rahal JJ. 2005 Fluoroquinolone-resistant *Streptococcus agalactiae*: epidemiology and mechanism of resistance. *Antimicrob Agents Chemother* 49:2495–2497 10.1128/AAC.49.6.2495-2497.2005. [PubMed: 15917553]
165. Hays C, Louis M, Plainvert C, Dmytruk N, Touak G, Trieu-Cuot P, Poyart C, Tazi A. 2016 Changing Epidemiology of Group B *Streptococcus* Susceptibility to Fluoroquinolones and Aminoglycosides in France. *Antimicrob Agents Chemother* 60:7424–7430. [PubMed: 27736761]
166. Piccinelli G, Gargiulo F, Corbellini S, Ravizzola G, Bonfanti C, Caruso A, De Francesco MA. 2015 Emergence of the first levofloxacin-resistant strains of *Streptococcus agalactiae* isolated in Italy. *Antimicrob Agents Chemother* 59:2466–2469 10.1128/AAC.05127-14. [PubMed: 25666148]
167. Park SY, Park Y, Chung JW, Huh HJ, Chae SL, Kim YA, Lee SS. 2014 Group B streptococcal bacteremia in non-pregnant adults: results from two Korean centers. *Eur J Clin Microbiol Infect Dis* 33:1785–1790 10.1007/s10096-014-2140-9. [PubMed: 24825185]
168. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Jr, Tleyjeh IM, Rybak MJ, Barsic B, Lockhart PB, Gewitz MH, Levison ME, Bolger AF, Steckelberg JM, Baltimore RS, Fink AM, O’Gara P, Taubert KA, American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. 2015 Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. *Circulation* 132:1435–1486 10.1161/CIR.0000000000000296. [PubMed: 26373316]



Figure 1:
Streptococcus agalactiae colonization rates in pregnant women.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2: Invasive group B *Streptococcus* disease and mortality in non-pregnant adults, United States, 2015. Incidence shown in blue; mortality shown in orange.




Figure 3:
Incidence of invasive group B *Streptococcus* disease in neonates, United States, 1997–2015.